Forfait Innovation in France
25 June 2021
Sunrise received approval from the French Ministry of Health for temporary reimbursement in France at 14 centers within the scope of the Forfait Innovation framework.
The innovation package consists of early and exceptional coverage of medical devices and innovative procedures, subject to the completion of clinical and possibly medico-economic studies to generate critical data. This is the first step toward long term reimbursement. Sunrise is the 14th company to receive a Forfait Innovation since its inception in 2009.
“Sunrise is the first diagnostic solution using artificial intelligence to be admitted in this selective fast track to reimbursement. This major milestone for Sunrise is a big recognition of all the clinical work validating the technology by the Sunrise team and the many investigators,” said Laurent Martinot co-founder and CEO.